Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Arch-backed obesity biotech launches with $290M
Clinical-stage Metsera has emerged from stealth with $290 million and the bold vision of ushering in the next generation of obesity treatments.
Gabrielle Masson
Apr 18, 2024 7:00am
FDA aims to boost trial innovation with new center at CDER
Apr 17, 2024 10:03am
Lilly's Prevail walks away from Precision gene editing collab
Apr 17, 2024 8:48am
Lilly glides out of Leqembi slipstream with FDA meeting request
Apr 17, 2024 5:00am
Roche, Lilly blood test for Alzheimer's expedited at FDA
Apr 11, 2024 11:06am
Avalo snaps up AlmataBio for ex-Lilly inflammatory drug
Mar 28, 2024 8:26am